Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $13.60 Average Target Price from Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $12.9091.

A number of analysts have weighed in on the company. Guggenheim reiterated a “buy” rating and set a $12.00 price target on shares of Compass Therapeutics in a report on Tuesday, March 24th. Stifel Nicolaus set a $6.00 price target on Compass Therapeutics in a report on Monday. William Blair reiterated an “outperform” rating on shares of Compass Therapeutics in a report on Thursday, March 5th. Wall Street Zen downgraded Compass Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Finally, Raymond James Financial downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 28th.

Compass Therapeutics Stock Up 1.0%

Shares of NASDAQ:CMPX opened at $2.10 on Monday. The firm has a market cap of $378.19 million, a P/E ratio of -5.12 and a beta of 0.89. Compass Therapeutics has a 12-month low of $1.61 and a 12-month high of $6.88. The business has a fifty day simple moving average of $3.63 and a 200 day simple moving average of $4.90.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). As a group, equities research analysts expect that Compass Therapeutics will post -0.44 EPS for the current year.

Institutional Trading of Compass Therapeutics

Several large investors have recently made changes to their positions in CMPX. Strs Ohio acquired a new stake in shares of Compass Therapeutics in the 1st quarter valued at about $34,000. Creative Planning acquired a new stake in shares of Compass Therapeutics in the 2nd quarter valued at about $30,000. XTX Topco Ltd acquired a new stake in shares of Compass Therapeutics in the 2nd quarter valued at about $84,000. Invesco Ltd. grew its stake in shares of Compass Therapeutics by 58.1% in the 2nd quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock valued at $153,000 after buying an additional 21,578 shares during the period. Finally, Adage Capital Partners GP L.L.C. grew its stake in shares of Compass Therapeutics by 11.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock valued at $11,505,000 after buying an additional 449,868 shares during the period. 68.43% of the stock is currently owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.